Journal ArticleDOI
Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma
Reads0
Chats0
TLDR
Current evidence for efficacy of preoperative therapy for locally advanced ESCC is reviewed and summarize to improve overall survival further.Abstract:
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer. Currently, neoadjuvant therapy in combination with surgical resection is the mainstay of treatment. However, the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines. With neoadjuvant chemoradiotherapy, chemotherapy, or emerging immunotherapy, continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further. Here, we review and summarize current evidence for efficacy of preoperative therapy for locally advanced ESCC.read more
Citations
More filters
Journal ArticleDOI
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang,Xiangbin Xing,Sai Ching J. Yeung,Si Yu Wang,Wenfang Chen,Yong Bao,Fang Wang,Shi-Ting Feng,Fang Peng,Xiaoyan Wang,Shuling Chen,Minghui He,Ningfang Zhang,Honglei Wang,Bo Zeng,Zhifeng Liu,Biniam Kidane,Christopher W. Seder,Kazuo Koyanagi,Yaron Shargall,Honghe Luo,Sui Peng,Chao Cheng +22 more
TL;DR: Neoadjuvant camrelizumab plus carboplatin and nab-paclitaxel had manageable treatment-related adverse effects and induced an objective response in 90.5% of patients, demonstrating its antitumor efficacy in resectable ESCC.
Journal ArticleDOI
Update on Management of Squamous Cell Esophageal Cancer
John K. Waters,Scott I. Reznik +1 more
TL;DR: Novel approaches to screening may be cost-effective in regions with a high incidence of ESCC and several recent studies have found a survival benefit to immunotherapy for patients with metastatic or persistent disease.
Journal ArticleDOI
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Wenwu He,Xue-Feng Leng,Tianqin Mao,Xi Luo,Ling Zhou,Jiaxin Yan,Lin Peng,Qiang Yang,Guangyuan Liu,Xingyun Wei,Kangning Wang,Chenghao Wang,Shan Zhang,Xudong Zhang,Xudong Shen,Depei Huang,Huan Yi,Ting Bei,Xueke She,Wenguang Xiao +19 more
TL;DR: The combination of toripalimab plus paclitaxel and carboplatin is safe, feasible, and effective in locally advanced resectable ESCC, indicating its potential as a neoadjuvant treatment for ESCC.
Journal ArticleDOI
OUP accepted manuscript
TL;DR: In this paper , toripalimab plus paclitaxel and carboplatin was used for locally advanced resectable esophageal squamous cell carcinoma (ESCC) patients.
Journal ArticleDOI
Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma
TL;DR: In this article , the authors used neutrophil-to-lymphocyte ratio (NLR), lymphocyte to-monocyte ratio(LMR), platelet-tolycky ratio (PLR), and systemic immune-inflammation index (SII) to predict pathological response to anti-PD-1 plus neoadjuvant chemotherapy, and cutoff values of these parameters were all determined by ROC curve analysis.
References
More filters
Journal ArticleDOI
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham,William H. Allum,Sally P. Stenning,Jeremy Thompson,Marianne Nicolson,J. Howard Scarffe,F. Lofts,Stephen Falk,Timothy Iveson,David Smith,Ruth E Langley,Monica Verma,Simon Weeden,Yu Jo Chua +13 more
TL;DR: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
DG Pfister,K. K. Ang,D Brizel +2 more
Journal ArticleDOI
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
TL;DR: Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer and the regimen was associated with acceptable adverse-event rates.
Journal ArticleDOI
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Fiebo J. W. ten Kate,Geert-Jan Creemers,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Herman van Dekken,Maurice J.C. van der Sangen,Tom Rozema,Katharina Biermann,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ate van der Gaast +29 more
TL;DR: Long-term follow-up confirms the overall survival benefits for neoadjuvant chemoradiotherapy in patients with clinically resectable, locally advanced cancer of the oesophagus or Oesophagogastric junction and shows a significant increase in 5-year overall survival.